Indication
For the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Medicine details
- Medicine name:
- vanzacaftor / tezacaftor / deutivacaftor (Alyftrek)
- SMC ID:
- SMC2800
- Pharmaceutical company
- Vertex Pharmaceuticals Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Publication due date:
- 09 March 2026